{"id":850913,"date":"2025-05-14T08:35:33","date_gmt":"2025-05-14T12:35:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/"},"modified":"2025-05-14T08:35:33","modified_gmt":"2025-05-14T12:35:33","slug":"ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/","title":{"rendered":"Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations"},"content":{"rendered":"<h2>\nNew entity, ErnexaTX2, reflects progress toward clinical readiness<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., May  14, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=giZxe0gAOZd7yQTLL4Y2efee_OSNJKIkYbSDYmNsNzERPSygRiu8bJgyOVD_6MZOrlpcHwTId05C_aAWjRGRLyzMrjFPT6dm83WzTiqo4LE=\" rel=\"nofollow\" target=\"_blank\"><u>Ernexa Therapeutics<\/u><\/a> (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary based in Texas. The new entity has been established to support ongoing preclinical development of the company\u2019s lead program, ERNA-101 for ovarian cancer, and to lay the operational groundwork for anticipated clinical activity in 2026.<\/p>\n<p>\u201cAs we continue to progress ERNA-101 through key preclinical milestones, we\u2019re also setting the stage for a seamless transition into clinical work,\u201d said Sanjeev Luther, President and CEO of Ernexa Therapeutics. \u201cThe formation of ErnexaTX2 reflects both our long-term commitment to the Texas ecosystem and our strategic readiness to support clinical manufacturing, regulatory interactions, and site activation in the years ahead.\u201d<\/p>\n<p>The subsidiary will support ongoing research being conducted under a sponsored research agreement with Michael Andreeff, M.D., Ph.D., from <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=USJLFiN0MFePat3d77JtIODpa42ylN90HvPoIF8IujCwHXJBYPy_3sH3eNfR7EaBHtZxgHrYmRHnZJpGqnZ2EDr3D15nStl1ZtXpQo5Jet1Zou4b8tDT8abnKNbdtSFrBMvDCpvNCcrDid8AJVRQnA==\" rel=\"nofollow\" target=\"_blank\"><u>The University of Texas MD Anderson Cancer Center<\/u><\/a>. Dr. Andreeff is an internationally recognized cell therapy expert and a longtime leader in targeting the tumor microenvironment in ovarian and other solid tumors.<\/p>\n<p>In parallel with scientific advancements, Ernexa continues to evolve its infrastructure in anticipation of future Investigational New Drug (IND)-enabling activities. With its new footprint in Texas, the company is positioned to accelerate clinical partnerships, navigate regulatory planning, and engage local biomanufacturing partners to support scale-up efforts.<\/p>\n<p>ERNA-101 remains on track for IND-enabling studies in 2025, with first-in-human studies targeted for 2026.<\/p>\n<p>\n        <strong>About Ernexa Therapeutics<\/strong>\n      <\/p>\n<p>Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa\u2019s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa\u2019s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting.<\/p>\n<p>ERNA-101 is the company\u2019s lead cell therapy product, designed to activate and regulate the immune system\u2019s response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company\u2019s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5Vk6RuKzYbZMKkLweecZTQeCj3bafSLzNQJW0OoAAipj2SF9GHXxN5Kf-2h-IyWTd4F6PzxzjMVvLvWHLEQlGYUzaZNY9YXi7v4ludUKm7c=\" rel=\"nofollow\" target=\"_blank\"><u>www.ernexatx.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cdesign,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201ccould,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccontemplate,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cobjective,\u201d or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa\u2019s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company\u2019s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa\u2019s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.<\/p>\n<p>\n        <strong>Media &amp; Investor Relations Contact<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fP1r4iTkU-DFj8RplstzqAFGhs3WbPdrKQrgxLUrJevWwT34mHqDe68eYc_aOyJL8HbIVrQ__Pjjg-sHKCusFIAvxjOOmrHzJsxMy-8Xxtg=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>investors@ernexatx.com<\/u><br \/>\n        <\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MTEzMCM2OTQwNDU4IzIyMTAyODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODBkNTY5MzMtNTEyYS00ZWY5LWE5ZTItZjYzMmUwN2U4ZDYzLTEyMjE4MzMtMjAyNS0wNS0xNC1lbg==\/tiny\/Ernexa-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>New entity, ErnexaTX2, reflects progress toward clinical readiness CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) &#8212; Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary based in Texas. The new entity has been established to support ongoing preclinical development of the company\u2019s lead program, ERNA-101 for ovarian cancer, and to lay the operational groundwork for anticipated clinical activity in 2026. \u201cAs we continue to progress ERNA-101 through key preclinical milestones, we\u2019re also setting the stage for a seamless transition into clinical work,\u201d said Sanjeev Luther, President and CEO of Ernexa Therapeutics. \u201cThe formation of ErnexaTX2 reflects both our long-term commitment to the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-850913","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"New entity, ErnexaTX2, reflects progress toward clinical readiness CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) &#8212; Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary based in Texas. The new entity has been established to support ongoing preclinical development of the company\u2019s lead program, ERNA-101 for ovarian cancer, and to lay the operational groundwork for anticipated clinical activity in 2026. \u201cAs we continue to progress ERNA-101 through key preclinical milestones, we\u2019re also setting the stage for a seamless transition into clinical work,\u201d said Sanjeev Luther, President and CEO of Ernexa Therapeutics. \u201cThe formation of ErnexaTX2 reflects both our long-term commitment to the &hellip; Continue reading &quot;Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-14T12:35:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MTEzMCM2OTQwNDU4IzIyMTAyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations\",\"datePublished\":\"2025-05-14T12:35:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\\\/\"},\"wordCount\":675,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MTEzMCM2OTQwNDU4IzIyMTAyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\\\/\",\"name\":\"Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MTEzMCM2OTQwNDU4IzIyMTAyODA=\",\"datePublished\":\"2025-05-14T12:35:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MTEzMCM2OTQwNDU4IzIyMTAyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MTEzMCM2OTQwNDU4IzIyMTAyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/","og_locale":"en_US","og_type":"article","og_title":"Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations - Market Newsdesk","og_description":"New entity, ErnexaTX2, reflects progress toward clinical readiness CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) &#8212; Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary based in Texas. The new entity has been established to support ongoing preclinical development of the company\u2019s lead program, ERNA-101 for ovarian cancer, and to lay the operational groundwork for anticipated clinical activity in 2026. \u201cAs we continue to progress ERNA-101 through key preclinical milestones, we\u2019re also setting the stage for a seamless transition into clinical work,\u201d said Sanjeev Luther, President and CEO of Ernexa Therapeutics. \u201cThe formation of ErnexaTX2 reflects both our long-term commitment to the &hellip; Continue reading \"Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-14T12:35:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MTEzMCM2OTQwNDU4IzIyMTAyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations","datePublished":"2025-05-14T12:35:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/"},"wordCount":675,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MTEzMCM2OTQwNDU4IzIyMTAyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/","name":"Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MTEzMCM2OTQwNDU4IzIyMTAyODA=","datePublished":"2025-05-14T12:35:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MTEzMCM2OTQwNDU4IzIyMTAyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MTEzMCM2OTQwNDU4IzIyMTAyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-establishes-texas-subsidiary-to-support-continued-development-of-erna-101-and-future-clinical-operations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/850913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=850913"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/850913\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=850913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=850913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=850913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}